Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05955014

Conditions

Von Hippel Lindau Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.

Conditions

Von Hippel Lindau Disease

Study ID

NCT05955014

Start date

Aug 24, 2023

Status verified date

Jun, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Presence of genetic confirmation or clinical criteria consistent with vHL disease.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients with psychiatric illness/social situations that would limit compliance with study requirements.

Study Design

Enrollment

125 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Progression-free survival (PFS) [ Time Frame: through study completion; an average of 1 year ]

Central Contacts and Locations

Central contacts

Eric Jonasch, MD

(713) 563-7232ejonasch@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Eric Jonasch, MD

713-563-7232ejonasch@mdanderson.org

Principal Investigator:

Eric Jonasch, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Jun 26, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-06-26.